



PAN MERSEY AREA PRESCRIBING COMMITTEE
PRESCRIBING POLICY STATEMENT
REF: PS121 FINAL
APC BOARD DATE: 29 NOV 2017



Pan Mersey
Area Prescribing Committee

AFLIBERCEPT intravitreal injection (Eylea®) for mCNV

RED

The Pan Mersey Area Prescribing Committee recommends the prescribing of AFLIBERCEPT intravitreal injection (Eylea®), by ophthalmologists only, for treating myopic choroidal neovascularisation (mCNV) in accordance with [NICE TA486](#).

NICE TA486 [1st November 2017] states:

- Aflibercept is recommended, within its marketing authorisation, as an option for treating visual impairment due to myopic choroidal neovascularisation in adults, only if the company provides aflibercept with the discount agreed in the patient access scheme. [1]
- If patients and their clinicians consider both aflibercept and ranibizumab to be suitable treatments, the least costly should be used, taking into account anticipated administration costs, dosage and price per dose. [1]

Ranibizumab is already recommended by NICE for treating choroidal neovascularisation. An indirect comparison of aflibercept and ranibizumab shows that both drugs provide similar overall health benefits. The total costs of aflibercept are the same as or less than those of ranibizumab.

Because it has similar costs and overall health benefits to ranibizumab, aflibercept is also recommended as a cost effective option for treating choroidal neovascularisation. [1]

Costing information – NICE do not think that this guidance will have a significant impact on NHS resources (defined as <£9,100 per 100,000 population) because the technology is an option alongside current standard treatment options. [2]

References

1. NICE TA486: Aflibercept for choroidal neovascularisation. Available online at: <https://www.nice.org.uk/guidance/ta486> [Last accessed 01/11/2017]
2. NICE TA486: Aflibercept for choroidal neovascularisation: resource impact statement. Available online at: <https://www.nice.org.uk/guidance/ta486/resources/resource-impact-statement-4659396013> [Last accessed 01/11/2017]

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.